EN DE
Watch Procter & Gamble Hygiene and Health Care Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Procter & Gamble Hygiene and Health Care Limited (PGHH) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Procter & Gamble Hygiene and Health Care Limited stock ₹7,733, price ₹6,867, upside +12.6%, quality 84 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Consumer Defensive IN · ISIN INE179A01014

PG Procter & Gamble Hygiene and Health Care Limited logo Broad data Nov 14, 2026

Procter & Gamble Hygiene and Health Care Limited

PGHH · NSE

Strong company, but only slightly cheap (11% below fair value) and falling price: meets 1 of 3 rules.

Get notified free when this changes
Fair value ₹7,733 · Undervalued 
Quality 84/100 
Solidly profitable · 18.6% net margin (TTM) 
Low debt 
Generates free cash flow 
Wide moat 89/100
Broad data 
115% return on equity. 
Mixed Growth (revenue 5y +3.7 %/yr in INR) 
3.8% dividend yield · Payout strained
Mixed vs. peers (8/14) 
Falling price (downtrend) 
Quality growth
Watch Procter & Gamble Hygiene and Health Care Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹17,420 ₹6,639 Fair Value ₹7,733 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range ₹6,639 – ₹17,420 · fair‑value band ₹5,403 – ₹11,020 · the ₹6,867 price screens below the ₹7,733 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Procter & Gamble Hygiene and Health Care in your weekly email

Every Wednesday you see whether Procter & Gamble Hygiene and Health Care is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Procter & Gamble Hygiene and Health Care Limited manufactures and sells branded packaged fast-moving consumer goods in the feminine care and healthcare businesses in India and internationally. It operates through Health care Products and Hygiene Products segments.

Show moreShow less

The company offers health care products, including ointments and creams, cough drops, and tablets; and hygiene products, such as feminine hygiene and other skin care hygiene products, as well as feminine care pads.

It also provides baby care products comprising nappies, pants, and baby wipes; grooming products; laundry products; hair care products; home, personal and skin care, and oral products.

The company sells its products under the Vicks, Whisper, Pampers, Ariel, Tide, Gillette, Head & Shoulders, Herbal Essences, Pantene, Ambi Pur, Oral-B, Olay, and Old Spice brands through mass merchandisers, as well as grocery, membership club, drug, department, and high frequency stores.

The company was incorporated in 1964 and is based in Mumbai, India. Procter & Gamble Hygiene and Health Care Limited operates as a subsidiary of The Procter & Gamble Company.

Stock analysis

Procter & Gamble Hygiene and Health Care Limited (PGHH) currently trades at ₹6,867, while our model-based Fair Value estimate is ₹7,733, implying the stock looks roughly 11% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of ₹4,435 per share, and 0 of the 26 models we run sit above the ₹6,867 price.

Bear case: the Economic Profit group reads lowest at ₹1,695, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.

Scenario range: ₹5,403 (bear) to ₹11,020 (bull), the price of ₹6,867 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 84/100 (high quality), in the Consumer Defensive sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Procter & Gamble Hygiene and Health Care Limited reported revenue of ₹42.8B in FY2026 versus ₹37.9B in FY2022, a compound +3.1%/yr. Reported net income was ₹8.6B in FY2026, compounding +10.4%/yr from FY2022.

Key figures

Market cap ₹223B (≈ $2.4B) Mid · P/E ratio 28.7 · P/S ratio 5.25 · EPS (TTM) ₹239.27 · Dividend yield 3.8% · Net margin 18.6% · Return on equity 115% · Return on assets (EBIT) 52.7% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 89 out of 100 (medium confidence).

What moves the price

The share trades about 46% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Consumer Defensive peers we cover trades at −32% fair-value upside, at 13%, PGHH screens cheaper than that median.

Fair Value models

Bear ₹5,403 Fair Value ₹7,733 Bull ₹11,020
Price ₹6,867 · Upside +12.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF ₹2,862 ₹4,265 ₹6,239 80
Growth DCF ₹2,861 ₹4,173 ₹5,947 78
Owner Earnings ₹2,884 ₹4,299 ₹6,289 76
All 26 models by family
DCF Models
FCF DCF ₹2,862 ₹4,265 ₹6,239 80
Owner Earnings ₹2,884 ₹4,299 ₹6,289 76
5Y Revenue Exit ₹2,027 ₹2,928 ₹4,059 73
5Y EBITDA Exit ₹3,141 ₹5,077 ₹7,379 75
5Y P/E Exit ₹3,490 ₹5,752 ₹8,192 70
10Y Revenue Exit ₹2,295 ₹3,174 ₹4,343 67
10Y EBITDA Exit ₹2,994 ₹4,571 ₹6,743 68
10Y P/E Exit ₹3,202 ₹5,010 ₹7,331 63
Earnings-Based
Graham-Dodd ₹1,794 ₹6,486 ₹8,746 64
Lynch FV ₹2,756 ₹3,938 ₹5,119 61
PEG = 1.0 ₹2,756 ₹3,938 ₹5,119 57
EPV ₹2,229 ₹2,513 ₹2,750 74
Dividend Discount
Gordon GGM ₹2,044 ₹3,714 ₹5,151 68
DDM Multi-Stage ₹2,044 ₹3,377 ₹3,964 67
Multiples
P/E Multiple ₹4,156 ₹5,541 ₹6,926 63
P/S Multiple ₹1,583 ₹2,110 ₹2,638 58
P/B Multiple ₹687.46 ₹916.61 ₹1,146 55
EV/EBIT ₹4,627 ₹6,112 ₹7,596 66
EV/EBITDA ₹3,692 ₹4,865 ₹6,037 67
EV/Revenue ₹1,560 ₹2,153 ₹2,747 54
Asset-Based
NCAV (Graham) ₹19.09 ₹28.93 ₹36.16 54
Growth DCF
Growth DCF ₹2,861 ₹4,173 ₹5,947 78
Rev-Margin DCF ₹2,027 ₹2,951 ₹4,068 73
Economic Profit
Residual Income ₹663.98 ₹839.26 ₹1,523 73
ROIC Compounder ₹2,246 ₹2,551 ₹2,818 72
Growth Earnings
Growth-Adj P/E ₹2,916 ₹4,166 ₹5,416 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 84/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 96
How much profit the company makes from its sales and capital
Quality Growth 31
Are margins and returns getting better?
Cashflow 75
Do the profits arrive as real cash?
Financial strength 92
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 94
How calm the share price moves, does not count
Price momentum 10
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 70/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−4.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.7%
Start year 2021 (pandemic). Over 10 years: +6.5% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.6%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+12.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+8.3%
Dividend (yield on the price)3.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.8.3% vs 7.3%, steady
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 27%
Pace: the 5-year rate starts in 2021 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+16.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +11.9% a year for the price.

Watch PGHH, get fair value alerts →

Compare Procter & Gamble Hygiene and Health Care Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 241 stocks

Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 84 · Top 25%
Fair Value upside +12.6% · Above median
Profitability
Return on equity (12 months) 114.9% · Top 25%
Return on assets 47.5% · Top 25%
Net margin (12 months) 18.6% · Top 25%
Operating margin (12 months) 24.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −4.9% · Bottom 25%
Dividend yield (12 months) 3.8% · Above median

Valuation Multiplesvs Household & Personal Products median · lower = cheaper

P/E (12 months) 28.7× · Pricier than median
P/B 29.58× · Priciest 25%
P/S (12 months) 5.25× · Priciest 25%
Price / free cash flow (fiscal year) 25.5× · Pricier than median
EV/EBITDA 20.2× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)50 · sector 32
FUTURE (revenue growth)0 · sector 21
PAST (return on equity)100 · sector 29
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)76 · sector 53

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Godrej Consumer Products Limited GODREJCP ₹892.70 ₹1,146 +28% vs PGHH
Puig Brands, S.A PUIG €20.40 €24.28 +19% vs PGHH
Henkel AG HEN €79.50 €83.75 +5% vs PGHH
Beiersdorf Aktiengesellschaft, BEI €83.46 €69.09 −17% vs PGHH
The Clorox Company CLX $109.46 $74.29 −32% vs PGHH
Church & Dwight Co CHD $113.00 $65.04 −42% vs PGHH
Colgate-Palmolive Company CL $99.67 $56.16 −44% vs PGHH
Marico Limited MARICO ₹913.65 ₹493.84 −46% vs PGHH
The Estée Lauder Companies Inc EL $111.75 $44.21 −60% vs PGHH
Hindustan Unilever Limited HINDUNILVR ₹2,000 ₹775.25 −61% vs PGHH

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Procter & Gamble Hygiene and Health Care Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Procter & Gamble Hygiene and Health Care Limited Fair Value". https://www.fairvalue-calculator.com/stock/PGHH

Frequently asked questions

Is Procter & Gamble Hygiene and Health Care Limited (PGHH) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of ₹7,733 versus a price of ₹6,867, about +13% upside (undervalued).
What is the fair value of PGHH?
Our model-based fair value for Procter & Gamble Hygiene and Health Care Limited is ₹7,733 (as of Nov 14, 2026), built from audited fundamentals. The current price: ₹6,867.
What is the quality score of PGHH?
Procter & Gamble Hygiene and Health Care Limited has a Quality Score of 84/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Procter & Gamble Hygiene and Health Care Limited (PGHH)?
Our model-based price target is the fair value of ₹7,733 (as of Nov 14, 2026) from 26 valuation models. Cautious scenario ₹5,403, optimistic scenario ₹11,020. It is a calculation from audited fundamentals, not an analyst target.
What is the Procter & Gamble Hygiene and Health Care Limited stock forecast for 2026?
Our models put fair value at ₹7,733, about +13% upside versus a price of ₹6,867 (undervalued). Cautious scenario ₹5,403, optimistic scenario ₹11,020. The calculation is refreshed regularly with new filings.
What is the revenue of Procter & Gamble Hygiene and Health Care Limited (PGHH)?
Procter & Gamble Hygiene and Health Care Limited reported trailing-twelve-month revenue of about ₹42.4B (latest available figure, as of Nov 14, 2026).
Does Procter & Gamble Hygiene and Health Care Limited pay a dividend?
Procter & Gamble Hygiene and Health Care Limited currently shows a dividend yield of 3.79% relative to its recent price (as of Nov 14, 2026).
How much is the dividend of Procter & Gamble Hygiene and Health Care Limited (PGHH) and when is the ex-dividend date?
Procter & Gamble Hygiene and Health Care Limited pays a dividend of ₹260.00 per share a year, a dividend yield of 3.8%. The last ex-dividend date was Sep 1, 2026. A dividend has been paid every year since at least 2008. The payout ratio is 109% of earnings. Free cash flow covers the dividend 1.04 times. Our assessment: Payout strained. The dividend exceeds reported earnings (though reported profit is often depressed by one-off charges), and free cash flow only just covers it (or coverage is unknown). Not an emergency, but little room for error.
What growth is priced into Procter & Gamble Hygiene and Health Care Limited (PGHH)?
For today's price to be fair in a discounted-cash-flow model, Procter & Gamble Hygiene and Health Care Limited would have to grow free cash flow by 16.5 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 3.7 % per year. As of Nov 14, 2026.
What discount rate (WACC) does the fair value of PGHH use?
Our models discount Procter & Gamble Hygiene and Health Care Limited at 10.9 %: a base by market capitalisation (mid), damped by beta 0.23, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Procter & Gamble Hygiene and Health Care Limited that is +16.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has Procter & Gamble Hygiene and Health Care Limited (PGHH) delivered so far?
Over the past 5 years revenue at Procter & Gamble Hygiene and Health Care Limited grew 3.7 % a year. The price currently implies free-cash-flow growth of +16.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Procter & Gamble Hygiene and Health Care Limited (PGHH) growing?
The median revenue growth in the sector is +4.0 % a year. That is the yardstick for the growth priced into Procter & Gamble Hygiene and Health Care Limited (+16.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Procter & Gamble Hygiene and Health Care Limited (PGHH)?
The free-cash-flow yield on the price is 3.92 %: that much free cash flow Procter & Gamble Hygiene and Health Care Limited produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Procter & Gamble Hygiene and Health Care Limited (PGHH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Procter & Gamble Hygiene and Health Care Limited it is ₹7,733 per share (as of Nov 14, 2026), against a price of ₹6,867. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Procter & Gamble Hygiene and Health Care Limited stock overvalued or undervalued in 2026?
As of Nov 14, 2026, PGHH trades below its calculated fair value: price ₹6,867, fair value ₹7,733, a gap of about +13% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PGHH?
No. The price is what the market pays today (₹6,867); the fair value is what the company's own numbers justify (₹7,733). For Procter & Gamble Hygiene and Health Care Limited the two are ₹866.00 per share apart. That gap is exactly why we show both numbers side by side.
How much is Procter & Gamble Hygiene and Health Care Limited worth?
The market values Procter & Gamble Hygiene and Health Care Limited at about ₹223B (market capitalisation, as of Nov 14, 2026). Per share that is ₹6,867; our models calculate a fair value of ₹7,733 per share.
What do the bullish and bearish scenarios say about PGHH?
Our models span a range for Procter & Gamble Hygiene and Health Care Limited: cautious scenario ₹5,403, base ₹7,733, optimistic ₹11,020 per share (as of Nov 14, 2026, price ₹6,867). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PGHH?
Procter & Gamble Hygiene and Health Care Limited trades at a price-to-earnings ratio of 28.7 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹7,733 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings: 71.7. Other multiples: P/B 29.6, P/S 5.3, EV/EBITDA 20.2.
How solid is the balance sheet of Procter & Gamble Hygiene and Health Care Limited (PGHH)?
Balance-sheet figures for Procter & Gamble Hygiene and Health Care Limited (as of Nov 14, 2026): return on equity 114.9%. They feed the Quality Score of 84/100, which measures business quality independently of the share price.
How far is PGHH from its 52-week high?
Procter & Gamble Hygiene and Health Care Limited trades at ₹6,867, about 46% below its 52-week high of ₹12,734 and 3% above the low of ₹6,639 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹7,733 is for.
Which stocks are comparable to Procter & Gamble Hygiene and Health Care Limited?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Procter & Gamble Hygiene and Health Care Limited stock attractive at the current price?
The data as of Nov 14, 2026: price ₹6,867, calculated fair value ₹7,733 (+13%), Quality Score 84/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PGHH calculated?
We run Procter & Gamble Hygiene and Health Care Limited through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹7,733 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Procter & Gamble Hygiene and Health Care Limited currently trades 11% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Procter & Gamble Hygiene and Health Care Limited (PGHH)?
The closing price on Nov 16, 2026 was ₹6,867. Our model-based fair value is ₹7,733, about +13% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Procter & Gamble Hygiene and Health Care Limited right now?
A fairly wide model range (₹5,403 to ₹11,020) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Procter & Gamble Hygiene and Health Care Limited (PGHH) come from?
Earnings per share at Procter & Gamble Hygiene and Health Care Limited grew 7.9 % a year from 2015 to 2026. Broken into its drivers: revenue per share +7.2 %, EBIT margin +0.5 %, tax rate +1.1 %, residual (interest, one-offs) −0.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Procter & Gamble Hygiene and Health Care Limited

How large is the market capitalisation of Procter & Gamble Hygiene and Health Care Limited (PGHH)?
The market capitalisation of Procter & Gamble Hygiene and Health Care Limited is ₹223B (≈ $2.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Procter & Gamble Hygiene and Health Care Limited (PGHH)?
The price-to-sales ratio of Procter & Gamble Hygiene and Health Care Limited is 5.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Procter & Gamble Hygiene and Health Care Limited (PGHH)?
Earnings per share at Procter & Gamble Hygiene and Health Care Limited are ₹239.27 (price ÷ EPS = P/E 28.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Procter & Gamble Hygiene and Health Care Limited (PGHH)?
The dividend yield of Procter & Gamble Hygiene and Health Care Limited is 3.8% (payout 109%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Procter & Gamble Hygiene and Health Care Limited (PGHH)?
The net margin of Procter & Gamble Hygiene and Health Care Limited is 18.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Procter & Gamble Hygiene and Health Care Limited (PGHH)?
The return on equity (ROE) of Procter & Gamble Hygiene and Health Care Limited is 115% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Procter & Gamble Hygiene and Health Care Limited (PGHH)?
On an EBIT basis the return on assets of Procter & Gamble Hygiene and Health Care Limited is 52.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Procter & Gamble Hygiene and Health Care Limited (PGHH)?
The operating margin of Procter & Gamble Hygiene and Health Care Limited is 24.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Procter & Gamble Hygiene and Health Care Limited (PGHH)?
Revenue at Procter & Gamble Hygiene and Health Care Limited is down 4.9% versus a year earlier (3y avg +3.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Procter & Gamble Hygiene and Health Care Limited (PGHH)?
Earnings per share at Procter & Gamble Hygiene and Health Care Limited are down 34.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Procter & Gamble Hygiene and Health Care Limited (PGHH) hold?
Procter & Gamble Hygiene and Health Care Limited holds more cash than debt, ₹5.7B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Procter & Gamble Hygiene and Health Care Limited in the live analysis

One click puts Procter & Gamble Hygiene and Health Care Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.